Literature DB >> 21557636

Peritoneal immune system in patients with advance epithelial ovarian cancer.

Iwona Wertel1, Aldona Nowicka, Ewelina Rogala, Jan Kotarski.   

Abstract

The development of epithelial ovarian cancer is associated with changes in the peritoneal cavity microenvironment. Tumor cells produce different factors, which impairs differentiation, maturation, and function of antigen-presenting cells. In this review, we focus on selected cell populations in the peritoneal cavity immune system and their potential role in epithelial ovarian cancer immunopathogenesis. We devote most attention to dendritic cells because they are considered to be superior in their antigen-presenting ability, compared with both macrophages and B lymphocytes. We also present a brief characterization of tumor-infiltraiting cells in epithelial ovarian cancer patients.

Entities:  

Mesh：

Year:  2011        PMID： 21557636     DOI： 10.3109/08830185.2011.569902

Source DB:  PubMed          Journal:  Int Rev Immunol        ISSN： 0883-0185            Impact factor:   5.311


  8 in total

1.  Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors.

Authors:  Anna Kanerva; Anniina Koski; Ilkka Liikanen; Minna Oksanen; Timo Joensuu; Otto Hemminki; Juni Palmgren; Kari Hemminki; Akseli Hemminki
Journal:  Mol Ther       Date:  2014-11-10       Impact factor: 11.454

2.  Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.

Authors:  Kristian Taipale; Ilkka Liikanen; Anniina Koski; Raita Heiskanen; Anna Kanerva; Otto Hemminki; Minna Oksanen; Susanna Grönberg-Vähä-Koskela; Kari Hemminki; Timo Joensuu; Akseli Hemminki
Journal:  Mol Ther       Date:  2016-04-04       Impact factor: 11.454

3.  Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.

Authors:  I Wertel; J Surówka; G Polak; B Barczyński; W Bednarek; J Jakubowicz-Gil; A Bojarska-Junak; J Kotarski
Journal:  Tumour Biol       Date:  2015-02-03

4.  Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape.

Authors:  Jörg Wischhusen; Sebastian F M Häusler; Itsaso Montalbán Del Barrio; Cornelia Penski; Laura Schlahsa; Roland G Stein; Joachim Diessner; Achim Wöckel; Johannes Dietl; Manfred B Lutz; Michel Mittelbronn
Journal:  J Immunother Cancer       Date:  2016-08-16       Impact factor: 13.751

5.  IGF1R Axis Inhibition Restores Dendritic Cell Antitumor Response in Ovarian Cancer.

Authors:  Lina Somri-Gannam; Shilhav Meisel-Sharon; Shay Hantisteanu; Gabriel Groisman; Ofer Limonad; Mordechai Hallak; Ilan Bruchim
Journal:  Transl Oncol       Date:  2020-05-16       Impact factor: 4.243

6.  Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model.

Authors:  Simone Pisano; Stefania Lenna; Gareth D Healey; Fereshteh Izardi; Lucille Meeks; Yajaira S Jimenez; Oscar S Velazquez; Deyarina Gonzalez; Robert Steven Conlan; Bruna Corradetti
Journal:  Clin Transl Med       Date:  2021-10

Review 7.  Myeloid-derived suppressor cells in ovarian cancer: friend or foe?

Authors:  Monika Walankiewicz; Ewelina Grywalska; Grzegorz Polak; Jan Kotarski; Dorota J Siwicka-Gieroba; Jacek Roliński
Journal:  Cent Eur J Immunol       Date:  2017-12-30       Impact factor: 2.085

8.  Ascites-derived IL-6 and IL-10 synergistically expand CD14+HLA-DR-/low myeloid-derived suppressor cells in ovarian cancer patients.

Authors:  Liangliang Wu; Zhaoyang Deng; Yaojun Peng; Lu Han; Jing Liu; Linxiong Wang; Bohua Li; Jian Zhao; Shunchang Jiao; Huafeng Wei
Journal:  Oncotarget       Date:  2017-08-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.